SpringWorks Therapeutics, Inc.   Report issue

Contributed to NME For profit Phase 2 Phase 3
Founded: Stamford CT United States (2017)

Organization Overview

First Clinical Trial
2019
NCT03905148
First Marketed Drug
2023
nirogacestat (Ogsiveo)
First NDA Approval
2023
nirogacestat (Ogsiveo)
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

SPRINGWORKS | SpringWorks Therapeutics, Inc.